Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge.

Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge. Clin Exp Immunol. 2020 May 22;: Authors: Patidar A, Selvaraj S, Chauhan P, Guzman CA, Ebenson T, Sarkar A, Chattopadhyay D, Saha B Abstract Solid tumors elicit suppressive T cell responses which impair antigen presenting cells (APCs) functions. Such an immune suppression results in uncontrolled tumor growth and mortality. Addressing APC dysfunction, dendritic cell (DC)-mediated anti-tumor vaccination was extensively investigated in both mice and humans. These studies never achieved full resistance to tumor relapse. Herein, we describe a repetitive RM-1 murine tumor rechallenge model for recurrence in humans. Using this newly developed model, we show that priming with tumor antigen-pulsed, TLR2 ligand-activated DCs elicits host-protective anti-tumor immune response in C57BL/6 mice. Upon stimulation with the TLR2 ligand peptidoglycan (PGN), the tumor antigen-pulsed DCs induce complete resistance to repetitive tumor challenges. Intra-tumoral injection of PGN reduces the tumor growth. The resistance to tumor is accompanied by increased expression of IL-27, T-bet, IL-12, TNF-α and IFN-γ along with heightened CTL functions. Mice primed four times with PGN-stimulated tumor antigen-pulsed DCs remain entirely resistant to repeat challenges with RM-1 tumor cells suggesting complete prevention of relapse and recurrence of tumor. Ad...
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research